Longeveron names Marie Washburn as CFO, effective July 13

Longeveron Inc. (NASDAQ: LGVN) has appointed Marie Washburn as Senior Vice President and Chief Financial Officer, effective July 13, 2026, according to a company statement. She also assumes the roles of principal financial officer and principal accounting officer.

Washburn succeeds Lisa Locklear, who is stepping down to pursue board opportunities and other professional and personal interests. Washburn had been serving as the company's Vice President and Corporate Controller since November 2025.

Before joining Longeveron, Washburn held leadership roles in the pharmaceutical and biotech sectors for more than 20 years. Her prior positions include Vice President of Finance at Fore Biotherapeutics Inc., multiple finance and accounting roles at Axcella Health Inc., Senior Director of Finance and Corporate Controller at Generation Bio, and Corporate Controller at Momenta Pharmaceuticals. She holds a B.S. in Business Administration from Bryant University.

Longeveron CEO Steven H. Willard said the company anticipates top-line results from its Phase 2b clinical trial evaluating laromestrocel as a potential treatment for Hypoplastic Left Heart Syndrome in the third quarter of 2026.

Longeveron is a clinical-stage biotechnology company based in Miami developing cellular therapies for rare pediatric and chronic aging-related conditions.

You May Also Be Interested In

• Longeveron adds Dr. Deborah Ascheim to its board of directors
• Neurocrine Biosciences names three senior vice presidents
• EU panel backs Gilead's Trodelvy plus Keytruda for breast cancer